Neurological Agents Chart
... Note: 10% of population lacks enzyme to do this Mu receptor agonist ...
... Note: 10% of population lacks enzyme to do this Mu receptor agonist ...
Mucoangin oromucosal spray, solution SmPC
... Mucoangin 2.5 mg/actuation oromucosal spray, solution can be used for up to 3 days. If symptoms worsen or still persist after 3 days or if the patient has a high fever, a doctor should be consulted. There have been very few reports of severe skin lesions such as Stevens-Johnson Syndrome and toxic ep ...
... Mucoangin 2.5 mg/actuation oromucosal spray, solution can be used for up to 3 days. If symptoms worsen or still persist after 3 days or if the patient has a high fever, a doctor should be consulted. There have been very few reports of severe skin lesions such as Stevens-Johnson Syndrome and toxic ep ...
U.S. Prescribing Information
... Carcinogenesis, Mutagenesis and Impairment of Fertility: CHEMET has not been tested for carcinogenic potential in long-term animal studies. CHEMET up to a dose of 510 mg/kg/day in males and 100 mg/kg/day in females did not show any adverse effect on fertility and reproductive performance. It was not ...
... Carcinogenesis, Mutagenesis and Impairment of Fertility: CHEMET has not been tested for carcinogenic potential in long-term animal studies. CHEMET up to a dose of 510 mg/kg/day in males and 100 mg/kg/day in females did not show any adverse effect on fertility and reproductive performance. It was not ...
Revised: March 2017 AN: 00756/2016 SUMMARY OF PRODUCT
... with a bioavailability of >75 %. However, there is a considerable variation between animals. Elimination of the drug from cat plasma is rapid with a half life of 4.5-5.0 hours. Peak plasma levels occur approximately 1-2 hours after dosing. Cmax is between 1.6-1.9 μg/ml. In rats thiamazole has been s ...
... with a bioavailability of >75 %. However, there is a considerable variation between animals. Elimination of the drug from cat plasma is rapid with a half life of 4.5-5.0 hours. Peak plasma levels occur approximately 1-2 hours after dosing. Cmax is between 1.6-1.9 μg/ml. In rats thiamazole has been s ...
Antithrombotic agents: Implications in dentistry ORAL MEDICINE
... ISI greater than 1.0 designates a less sensitive thromboplastin, whereas a value less than 1.0 indicates a more sensitive thromboplastin. This allows uniformity of the results from different laboratories by the introduction of the international normalized ratio (INR), which is calculated by the form ...
... ISI greater than 1.0 designates a less sensitive thromboplastin, whereas a value less than 1.0 indicates a more sensitive thromboplastin. This allows uniformity of the results from different laboratories by the introduction of the international normalized ratio (INR), which is calculated by the form ...
門診處方討論 主講者:黃意文
... hydration, and pelvic rest have not been proved effective and are not recommended routinely. B. TOCOLYTICS: Cornerstone of primary pharmacologic management. May lengthen duration of pregnancy by several days to allow time for steroid administration and possible transfer to a tertiary care facility ...
... hydration, and pelvic rest have not been proved effective and are not recommended routinely. B. TOCOLYTICS: Cornerstone of primary pharmacologic management. May lengthen duration of pregnancy by several days to allow time for steroid administration and possible transfer to a tertiary care facility ...
phera-plex - AnabolicMinds.com
... yield great gains in size and strength. More experienced androgen users can also potentially use Phera-Plex™ alongside other androgens with low androgenicity to get the most out of their cycles. ...
... yield great gains in size and strength. More experienced androgen users can also potentially use Phera-Plex™ alongside other androgens with low androgenicity to get the most out of their cycles. ...
Blexten - aralez pharmaceuticals
... Pregnant Women There are no adequate and well-controlled studies in pregnant women. Until such data become available, BLEXTEN™ should be avoided during pregnancy, unless advised otherwise by a physician. Animal studies do not indicate major direct or indirect harmful effects with respect to reproduc ...
... Pregnant Women There are no adequate and well-controlled studies in pregnant women. Until such data become available, BLEXTEN™ should be avoided during pregnancy, unless advised otherwise by a physician. Animal studies do not indicate major direct or indirect harmful effects with respect to reproduc ...
Flurium - Beximco Pharmaceuticals Ltd.
... In pregnancy: There is no data to support the use of flunarizine during pregnancy. Therefore it should not be administered to pregnant women unless the anticipated benefits outweigh the potential risks. In lactation: Animal studies have shown that flunarizine is excreted in breast milk. Therefore br ...
... In pregnancy: There is no data to support the use of flunarizine during pregnancy. Therefore it should not be administered to pregnant women unless the anticipated benefits outweigh the potential risks. In lactation: Animal studies have shown that flunarizine is excreted in breast milk. Therefore br ...
NEONATAL ABSTINENCE SYNDROME
... muscle tone, respirations and Moro reflex. Newborns should be observed for 20 to 30 minutes before scoring is determined. ...
... muscle tone, respirations and Moro reflex. Newborns should be observed for 20 to 30 minutes before scoring is determined. ...
zymar - Vision Institute Of Canada
... skeletal/craniofacial malformations or delayed ossification, atrial enlargement, and reduced fetal weight were observed in fetuses from rats given ≥150 mg/kg/day (approximately 3000-fold higher than the maximum recommended ophthalmic dose). In a perinatal/postnatal study, increased late post-implant ...
... skeletal/craniofacial malformations or delayed ossification, atrial enlargement, and reduced fetal weight were observed in fetuses from rats given ≥150 mg/kg/day (approximately 3000-fold higher than the maximum recommended ophthalmic dose). In a perinatal/postnatal study, increased late post-implant ...
Management of Constipation in Palliative Care
... An understanding of the patient’s normal, accepted bowel habit is essential when planning treatment All patients on opioids require a laxative, prescribed regularly (not prn) A combination of stimulant and softener is usually required Laxative doses often need to be increased along with increased do ...
... An understanding of the patient’s normal, accepted bowel habit is essential when planning treatment All patients on opioids require a laxative, prescribed regularly (not prn) A combination of stimulant and softener is usually required Laxative doses often need to be increased along with increased do ...
Latanoprost Orifarm eye drops, solution ENG SmPC
... Latanoprost may gradually change eye colour by increasing the amount of brown pigment in the iris. Before treatment is instituted, patients should be informed of the possibility of a permanent change in eye colour. Unilateral treatment can result in permanent heterochromia. This change in eye colour ...
... Latanoprost may gradually change eye colour by increasing the amount of brown pigment in the iris. Before treatment is instituted, patients should be informed of the possibility of a permanent change in eye colour. Unilateral treatment can result in permanent heterochromia. This change in eye colour ...
Objectives Possible Generics in 2013
... 5,599 patients with afib for whom warfarin was unsuitable Apixaban vs aspirin 81-324 mg daily ...
... 5,599 patients with afib for whom warfarin was unsuitable Apixaban vs aspirin 81-324 mg daily ...
Azeptin Azeptin
... the plasma concentration reached a steady state within 6 days and the biological half-life was found to be about 16.5 hr. ...
... the plasma concentration reached a steady state within 6 days and the biological half-life was found to be about 16.5 hr. ...
Heart Failure
... •Bradykinin and other kinins- stimulate production of NO, cyclic GMP, vasoactive eicosanoids that dilate the blood vessels, oppose angiotensin II effect on smooth muscle cells of blood vessels and fibroblasts proliferation & extracellular matrix deposition in heart ...
... •Bradykinin and other kinins- stimulate production of NO, cyclic GMP, vasoactive eicosanoids that dilate the blood vessels, oppose angiotensin II effect on smooth muscle cells of blood vessels and fibroblasts proliferation & extracellular matrix deposition in heart ...
Effect of Monthly Injectable Contraceptive (Mesigyna) on the Uterus
... on the uterus through binding to specific hormone binding proteins known as progesterone receptors (PRs). PRs are nuclear proteins found in epithelial, stromal and smooth muscle cells of the uterus. These receptors have high affinity to progesterone and can be detected by immunohistochemical assays ...
... on the uterus through binding to specific hormone binding proteins known as progesterone receptors (PRs). PRs are nuclear proteins found in epithelial, stromal and smooth muscle cells of the uterus. These receptors have high affinity to progesterone and can be detected by immunohistochemical assays ...
Clofibric acid
... Chronic oral toxicity studies in mice (up to 32 mg/kg/day; 96 mg/m2/day) did not indicate a carcinogenic potential for ketoprofen. A 2-year carcinogenicity study in rats, using doses up to 6.0 mg/kg/day (36 mg/m2/day), showed no evidence of tumorigenic potential. Abnormal spermatogenesis or inhibiti ...
... Chronic oral toxicity studies in mice (up to 32 mg/kg/day; 96 mg/m2/day) did not indicate a carcinogenic potential for ketoprofen. A 2-year carcinogenicity study in rats, using doses up to 6.0 mg/kg/day (36 mg/m2/day), showed no evidence of tumorigenic potential. Abnormal spermatogenesis or inhibiti ...
Cefadian - Avita Farma
... In cavies and rabbits 3.1 - 6.2 g drug respectively 0.78 - 1.56 g extract did not show any evidences of a harmful effect (Bliss 1940). ...
... In cavies and rabbits 3.1 - 6.2 g drug respectively 0.78 - 1.56 g extract did not show any evidences of a harmful effect (Bliss 1940). ...
DESCRIPTION TRELSTAR LA contains a pamoate salt of triptore
... is contraindicated in women who are or may become pregnant while receiving the drug. Studies in pregnant rats administered triptorelin at doses of 2, 10, and 100 mcg/kg/day (approximately equivalent to 0.2, 0.8, and 8 times the recommended human therapeutic dose based on body surface area) during th ...
... is contraindicated in women who are or may become pregnant while receiving the drug. Studies in pregnant rats administered triptorelin at doses of 2, 10, and 100 mcg/kg/day (approximately equivalent to 0.2, 0.8, and 8 times the recommended human therapeutic dose based on body surface area) during th ...
Aithal, 1999
... How does warfarin work • Interacts with KO reductase enzyme to prevent reduction of oxidized vitamin K • Reduced vitamin K is required for carboxylation of Glu residues to Gla residues in a number of blood coagulation proteases and other proteins • Gla residues give the proteins Ca2+ binding proper ...
... How does warfarin work • Interacts with KO reductase enzyme to prevent reduction of oxidized vitamin K • Reduced vitamin K is required for carboxylation of Glu residues to Gla residues in a number of blood coagulation proteases and other proteins • Gla residues give the proteins Ca2+ binding proper ...
Vaginitis Presentation
... Amphtericin B Pharmacokinetic: Poorly absorbed from GIT. Start with small initial dose then gradually increase it. An elimination half-life approximately 15 days. Amphotericin B circulating in plasma is highly bound (>90%) to plasma proteins. Amphotericin B is excreted very slowly (over weeks to mo ...
... Amphtericin B Pharmacokinetic: Poorly absorbed from GIT. Start with small initial dose then gradually increase it. An elimination half-life approximately 15 days. Amphotericin B circulating in plasma is highly bound (>90%) to plasma proteins. Amphotericin B is excreted very slowly (over weeks to mo ...
Stage-Specific Treatment of Malaria
... deaths. (Malaria caused by other species is rarely fatal but is more difficult to cure ...
... deaths. (Malaria caused by other species is rarely fatal but is more difficult to cure ...
AN: 01422/2012 Revised: May 2013 SUMMARY OF PRODUCT
... Indications for use, specifying the target species For the treatment of infections caused by organisms sensitive to oxytetracycline in horses, cattle, sheep and pigs. In vitro, oxytetracycline is active against a range of both Gram-positive and Gram-negative micro organisms including: ...
... Indications for use, specifying the target species For the treatment of infections caused by organisms sensitive to oxytetracycline in horses, cattle, sheep and pigs. In vitro, oxytetracycline is active against a range of both Gram-positive and Gram-negative micro organisms including: ...
A Quick Note
... Low metabolic activity (proteins) , Reduced first-pass effects Permeable, relatively easy to administer, Prolonged retention When the oral route is unfeasible (patient’s issues or drug’s) Potential to achieve zero-order controlled release ...
... Low metabolic activity (proteins) , Reduced first-pass effects Permeable, relatively easy to administer, Prolonged retention When the oral route is unfeasible (patient’s issues or drug’s) Potential to achieve zero-order controlled release ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.